Halozyme Therapeutics Inc., of San Diego, appointed Daniel Von Hoff to its scientific advisory board.
Illumina Inc., of San Diego, appointed Karin Eastham to its board.
Kalypsys Inc., of San Diego, appointed John McKearn president and chief scientific officer, and added Kenneth Langone and Al Heller to its board.
Kos Pharmaceuticals Inc., of Miami, appointed Kevin Ferro to its board.
Lexicon Genetics Inc., of The Woodlands, Texas, elected Clayton Rose to its board and its audit committee.
Maseci Biotech, of Worcester, Mass., appointed John McCarty senior scientist, specializing in assay development.
Maxim Pharmaceuticals Inc., of San Diego, appointed Richard Mafrica vice president of commercialization.
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., appointed Brian Hamilton vice president of clinical and regulatory affairs.
Millenia Hope Inc., of Montreal, appointed Alexander Kavic vice chairman of its board.
Millennium Pharmaceuticals Inc., of Cambridge, Mass., promoted Marsha Fanucci senior vice president and chief financial officer.
MultiCell Technologies Inc., of Warwick, R.I., retained Janice DiPietro as its chief financial officer.
Nuvelo Inc., of Sunnyvale, Calif., appointed Simon Allen vice president of business development and Lee Bendekgey chief financial officer, and promoted Gary Titus to vice president of finance and chief accounting officer.
OpGen Inc., of Madison, Wis., appointed Thomas Pyle and James Ogle to its board.